Cabaletta Bio, Inc. (CABA)

NASDAQ: CABA · IEX Real-Time Price · USD
7.53
+0.06 (0.80%)
Mar 24, 2023, 4:00 PM EDT - Market closed
0.8%
Market Cap 236.00M
Revenue (ttm) n/a
Net Income (ttm) -52.98M
Shares Out 31.34M
EPS (ttm) -1.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 210,292
Open 7.31
Previous Close 7.47
Day's Range 7.20 - 7.58
52-Week Range 0.59 - 12.88
Beta 2.57
Analysts Buy
Price Target 13.77 (+82.87%)
Earnings Date May 11, 2023

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune b... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2019
Employees 57
Stock Exchange NASDAQ
Ticker Symbol CABA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $13.77, which is an increase of 82.87% from the latest price.

Price Target
$13.77
(82.87% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is This the Most Lucrative Way to Play AI?

Biotech is all over the 52-week high leaderboard

Other symbols: ARDXETNBIDNAMHUAVRNA
1 week ago - InvestorPlace

Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell therapy, with potential to generate initial clinical...

1 week ago - GlobeNewsWire

Cabaletta Bio to Present at the Cowen 43rd Annual Health Care Conference

PHILADELPHIA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

3 weeks ago - GlobeNewsWire

Here's Why Cabaletta Bio, Inc. (CABA) is a Great Momentum Stock to Buy

Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Cabaletta Bio, Inc. (CABA) Is a Great Choice for 'Trend' Investors, Here's Why

Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed th...

1 month ago - Zacks Investment Research

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

2 months ago - GlobeNewsWire

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Other symbols: VRNAWVE
3 months ago - Zacks Investment Research

Can Cabaletta Bio, Inc. (CABA) Climb 60% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Cabaletta Bio, Inc. (CABA) points to a 60% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

3 months ago - Zacks Investment Research

Cabaletta Bio to Present at the 5th Annual Evercore ISI HealthCONx Conference

PHILADELPHIA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

4 months ago - GlobeNewsWire

Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapie...

4 months ago - GlobeNewsWire

5 Stocks Insiders Are Buying in October

According to the Insider Cluster Buys screen, a Premium feature of GuruFocus, five stocks that had a high number of company insiders buying shares over the past month were CNB Financial Corp. ( CCNE ,...

Other symbols: CCNEEVAMBINPLAY
5 months ago - GuruFocus

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patie...

6 months ago - GlobeNewsWire

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for pati...

7 months ago - GlobeNewsWire

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patie...

7 months ago - GlobeNewsWire

Cabaletta Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

PHILADELPHIA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patie...

8 months ago - GlobeNewsWire

What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

10 months ago - Zacks Investment Research

Cabaletta Bio's Updated Interim DSG3-CAART Data Fails To Cheer Investors

Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that affect...

11 months ago - Benzinga

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

PHILADELPHIA, May 18, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patien...

11 months ago - GlobeNewsWire

Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update

– DesCAARTes™ trial clinical and translational data from cohorts A3 and A4 and 28-day safety data from cohort A5 expected to be presented at upcoming scientific meetings in mid-2022 –

11 months ago - GlobeNewsWire

Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at Upcoming Scientific Meetings in May

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patien...

11 months ago - GlobeNewsWire

CABA LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Cabaletta Bio, Inc

New York, New York--(Newsfile Corp. - April 29, 2022) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Cabaletta Bio, In...

11 months ago - Newsfile Corp

CABA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 29, 2022 in the Class Action Filed on Behalf of Cabaletta Bio, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - April 29, 2022) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cabaletta Bio, Inc. (NASDAQ: CABA) allegi...

11 months ago - Newsfile Corp

Bronstein, Gewirtz & Grossman, LLC Reminds Cabaletta Bio, Inc. (CABA) Investors of Class Action Deadline and Last Few Hours to Actively Participate

New York, New York--(Newsfile Corp. - April 29, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cabaletta Bio, Inc. ("Cabaletta" or "th...

11 months ago - Newsfile Corp

CABA LAWSUIT ALERT: Levi & Korsinsky Notifies Cabaletta Bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - April 29, 2022) - Levi & Korsinsky, LLP notifies investors in Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ: CABA) of a class action securities lawsu...

11 months ago - Newsfile Corp

Deadline Today Alert: The Schall Law Firm Encourages Investors in Cabaletta Bio, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - April 29, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cabaletta Bio, I...

11 months ago - Newsfile Corp